- Report
- December 2022
- 91 Pages
Asia Pacific
From €1365EUR$1,500USD£1,170GBP
- Report
- December 2022
- 90 Pages
Middle East, Africa
From €1365EUR$1,500USD£1,170GBP
- Report
- December 2022
- 90 Pages
Europe
From €1365EUR$1,500USD£1,170GBP
- Report
- November 2023
- 200 Pages
Global
€4546EUR$4,995USD£3,897GBP
- Clinical Trials
- January 2020
- 1140 Pages
Global
From €2730EUR$3,000USD£2,341GBP
- Book
- July 2023
- 320 Pages
The Selective Estrogen Receptor Modulators (SERMs) market is a subset of the Women's Health market, focusing on the use of SERMs to treat a variety of conditions related to female reproductive health. SERMs are a type of drug that can act as either an agonist or antagonist of the estrogen receptor, depending on the tissue type. This allows them to be used to treat conditions such as endometriosis, uterine fibroids, and menopausal symptoms. SERMs can also be used to reduce the risk of breast cancer and osteoporosis.
SERMs are available in both oral and topical forms, and are often used in combination with other treatments. They are generally considered to be safe and effective, with few side effects.
Some companies in the SERMs market include Pfizer, Novartis, AstraZeneca, and Eli Lilly. Show Less Read more